New antibody TST001 takes on stomach and pancreatic cancers
NCT ID NCT04396821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junction, or pancreatic cancers. The main goals are to check safety, find the best dose, and see how the body handles the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TST001 (an experimental antibody targeting Claudin 18.2 on cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for advanced stomach, pancreatic, and other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial focused on safety and dosing, so it is not yet known if TST001 will shrink tumors or improve survival. Side effects from the drug or combinations are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Hospital
Pittsburgh, Pennsylvania, 15212, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Emory University
Atlanta, Georgia, 30033, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Gabrail Cancer Research
Canton, Ohio, 44718, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
-
NEXT Oncology
Austin, Texas, 78704, United States
-
Pennsylvania Cancer Specialist Research Institute
Gettysburg, Pennsylvania, 17325, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Stony Brook Cancer Center
Stony Brook, New York, 11794, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of Kansas, School of Medicine
Kansas City, Kansas, 66160, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
-
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
-
Washington University
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06519, United States